Gene expression quantification of selected oncogenes and tumor suppressor genes, involved in this pathway showed that KRAS and BCL2 were consistently upregulated in prostate tumor specimen, whereas PTEN was consistently downregulated. This evidence concerns the gene KRAS and prostate neoplasm.